Trial · NCT00106119

Thyroid and Glucose and Energy Metabolism

NCT00106119, Phase 2, Completed, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); results first posted 2015-02-23

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Thyroid and Glucose and Energy Metabolism. Trials, record NCT00106119. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00106119

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Thyroid and Glucose and Energy Metabolism
NCT number: NCT00106119
Status: Completed
Phases: Phase 2
Enrollment: 18 participants, actual
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions: Thyroid Diseases
Interventions: Liothyronine and Levothyroxine
First posted: 2005-03-21
Last updated: 2015-02-23
Results first posted: 2015-02-23

Source ClinicalTrials.gov

Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase	One month of therapy.
Primary	Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase	One month of therapy
Secondary	Total Cholesterol at Levothyroxine Treatment Phase	One month of therapy.
Secondary	Total Cholesterol at Liothyronine Treatment Phase	One month of therapy.
Secondary	Triglycerides at Levothyroxine Treatment Phase	One month of therapy.
Secondary	Triglycerides at Liothyronine Treatment Phase	One month of therapy.
Secondary	Resting Energy Expenditure at Levothyroxine Treatment Phase	One month of therapy.
Secondary	Resting Energy Expenditure at Liothyronine Treatment Phase	One month of therapy.
Secondary	Left Ventricle Mass Index at Levothyroxine Treatment Phase	One month of therapy.
Secondary	Left Ventricle Mass Index at Liothyronine Treatment Phase	One month of therapy.

1 to 10 of 14Source ClinicalTrials.gov

See all 14 registered outcomes

Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase	One month of therapy.	mg/kg/min	MEAN
SECONDARY	Total Cholesterol at Levothyroxine Treatment Phase	One month of therapy.	mg/dl	MEAN
PRIMARY	Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase	One month of therapy	mg/kg/min	MEAN
SECONDARY	Total Cholesterol at Liothyronine Treatment Phase	One month of therapy.	mg/dl	MEAN
SECONDARY	Triglycerides at Levothyroxine Treatment Phase	One month of therapy.	mg/dl	MEAN
SECONDARY	Triglycerides at Liothyronine Treatment Phase	One month of therapy.	mg/dl	MEAN
SECONDARY	Resting Energy Expenditure at Levothyroxine Treatment Phase	One month of therapy.	kcal/24 hour	MEAN
SECONDARY	Resting Energy Expenditure at Liothyronine Treatment Phase	One month of therapy.	kcal/24 hour	MEAN
SECONDARY	Left Ventricle Mass Index at Levothyroxine Treatment Phase	One month of therapy.	g/m^2	MEAN
SECONDARY	Left Ventricle Mass Index at Liothyronine Treatment Phase	One month of therapy.	g/m^2	MEAN

1 to 10 of 14Source ClinicalTrials.gov

See all 14 outcomes

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	7.26	Standard Deviation 2.7	mg/kg/min
Total Cholesterol at Levothyroxine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	196	Standard Deviation 26	mg/dl
Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	7.37	Standard Deviation 4.4	mg/kg/min
Total Cholesterol at Liothyronine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	174	Standard Deviation 28	mg/dl
Triglycerides at Levothyroxine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	152	Standard Deviation 31	mg/dl
Triglycerides at Liothyronine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	144	Standard Deviation 16	mg/dl
Resting Energy Expenditure at Levothyroxine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	1201	Standard Deviation 282	kcal/24 hour
Resting Energy Expenditure at Liothyronine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention ArmArm	1177	Standard Deviation 323	kcal/24 hour
Left Ventricle Mass Index at Levothyroxine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	71	Standard Deviation 16	g/m^2
Left Ventricle Mass Index at Liothyronine Treatment Phase	Liothyronine/Levothyroxine Therapy Intervention Arm	71	Standard Deviation 19	g/m^2

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention	STARTED	Liothyronine First, Then Levothyroxine	7
First Intervention	STARTED	Levothyroxine First, Then Liothyronine	7
First Intervention	COMPLETED	Liothyronine First, Then Levothyroxine	7
First Intervention	COMPLETED	Levothyroxine First, Then Liothyronine	7
First Intervention	NOT COMPLETED	Liothyronine First, Then Levothyroxine	0
First Intervention	NOT COMPLETED	Levothyroxine First, Then Liothyronine	0
Washout Period of 30 Days	STARTED	Liothyronine First, Then Levothyroxine	7
Washout Period of 30 Days	STARTED	Levothyroxine First, Then Liothyronine	7
Washout Period of 30 Days	COMPLETED	Liothyronine First, Then Levothyroxine	7
Washout Period of 30 Days	COMPLETED	Levothyroxine First, Then Liothyronine	7

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events4

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	generalized anxiety disorder	Psychiatric disorders	Levothyroxine Period	1	14	14
other	generalized anxiety disorder	Psychiatric disorders	Liothyronine Period	0	14	0
serious	General disorders	General disorders	Levothyroxine Period	0	14	0
serious	General disorders	General disorders	Liothyronine Period	0	14	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Levothyroxine Period
Total, all-cause mortality	Liothyronine Period
Total, other adverse events	Levothyroxine Period	1	14
Total, other adverse events	Liothyronine Period	0	14
Total, serious adverse events	Levothyroxine Period	0	14
Total, serious adverse events	Liothyronine Period	0	14

Source ClinicalTrials.gov

Papers6

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
6423430	BACKGROUND	PubMed
10614643	BACKGROUND	PubMed
11238510	BACKGROUND	PubMed
20447070	DERIVED	PubMed
21865366	DERIVED	PubMed
23585666	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Levothyroxine Period vs Liothyronine Period: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00106119

GET https://conductscience.org/api/trials/v1/NCT00106119/registered

API reference For AI assistants